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Abstract: Medullary thyroid cancer (MTC) is a rare malignancy with a poor prognosis. First line
therapy is surgery, which is the only curative method of the disease. However, in non-operable cases
or with tumor progression and metastases, a systemic treatment is necessary. This form of cancer
is often insensitive to conventional chemotherapy, but the use of tyrosine kinase inhibitors (TKIs),
such as pazopanib, cabozantinib, and vandetanib, has shown promising results with an increase in
progression-free survival and prolonged lifetime. Therefore, we focused on the pharmacological
characteristics of TKIs, their mechanism of action, their application as a secondary treatment option
for MTC, their efficacy as a cancer drug treatment, and reviewed the ongoing clinical trials. TKIs
also act systemically causing various adverse events (AEs). One common AE of this treatment is
hypertension, known to be associated with cardiovascular disease and can therefore potentially
worsen the well-being of the treated patients. The available treatment strategies of drug-induced
hypertension were discussed. The mechanism behind the development of hypertension is still
unclear. Therefore, the treatment of this AE remains symptomatic. Thus, future studies are necessary
to investigate the link between tumor growth inhibition and hypertension. In addition, optimized,
individual treatment strategies should be implemented.
Keywords: medullary thyroid carcinoma; hypertension; VEGF; antiangiogenesis; tyrosine
kinase inhibitors
1. Introduction
The medullary thyroid carcinoma (MTC) occurs in two forms: sporadic (75%) and hereditary
(25%), in most cases with mutations in the proto-oncogene tyrosine-protein kinase receptor gene RET.
Upon diagnosis, the most common treatment method of the disease is surgical intervention, including
total thyroidectomy and central neck dissection, given that metastatic spread to cervical lymph nodes is
a common event. Surgical cure is possible, but in progressive cases of the disease and distant metastatic
spread, this treatment method is not sufficient [1]. Distant metastases are present in 13–15% of cases,
and occur most often in the lungs, liver, and bone. These patients have a poor prognosis. The metastatic
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disease-form of MTC needs a systemic treatment, but is insensitive to conventional chemotherapy,
external beam radiation, and radioactive iodine therapy for thyroid cancer (TC). Therefore, a targeted
therapy is needed. Tyrosine kinase inhibitors (TKIs), such as pazopanib and cabozantinib, are proposed
as a promising new therapeutic option. TKIs work by blocking internal signaling cascades involved
in the induction of angiogenesis, an important process for the tumor to acquire enough nutrients for
further expansion [1,2]. However, such therapies also have adverse effects (AEs), and for tyrosine
kinase inhibitors, two of the most common side effects are proteinuria and hypertension [3].
2. Thyroid Cancer
Depending on the cells of origin, several thyroid cancer types can be distinguished. The dominant
form of thyroid cancer is differentiated thyroid cancer (DTC), caused by a malignant transformation of
the follicular cells (FCs). There are two forms of DTC: papillary thyroid cancer (PTC) and follicular
thyroid cancer (FTC) [4]. Rare forms of cancer developed in the FCs are poorly differentiated thyroid
cancer (PDTC) and anaplastic thyroid cancer (ATC) [5]. When malignant transformations occur in the
parafollicular cells (C cells), the resulting cancer characteristics differ in many ways from other forms
of thyroid cancer, i.e., in their lack of iodine uptake. This form is known as MTC [4].
Of all thyroid malignancies, MTC accounts for about 2%, which translates into roughly 1000 new
cases per year in the U.S. [6]. In Denmark, MTC accounts for 8% of all thyroid cancers, but it is still the
rarest form [7]. MTC appears in two variants: a sporadic form that develops in 75% of cases, and an
inherited form that is linked to a germ-line mutation of the RET proto-oncogene. The inherited form is
divided into three subgroups, depending on the clinical manifestations and findings caused by the
different mutations of the RET gene. They are known as multiple endocrine neoplasia (MEN) type 2A,
MEN type 2B, and as familial MTC (FMTC), respectively. The RET gene codes for a receptor tyrosine
kinase (RTK), which upon stimulation, promotes cell proliferation and differentiation [8]. Mutations in
the RET gene are the cause in 43% of the sporadic form incidents, and their presence is believed to be
associated with a more persistent disease and lower overall survival [9].
MTC is highly likely to spread to the regional lymph nodes, and more distant metastases in liver,
lungs, and bones occur occasionally as a result of the rich lymphatic drainage and vascularization
of the thyroid. A lymphatic spread has often already occurred by the time of diagnosis. With MTC
not being sensitive to either of the non-surgical treatments (radioactive iodine therapy, external beam
radiation, conventional therapy), the first line treatment is a thyroidectomy combined with lymph node
dissection. Regardless, the need for sustainable systemic treatment options remains [10]. The current
therapy 10-year survival rate is 76.5–80.5%, but in patients with distant metastases, this drops to
40% [11,12].
3. Tyrosine Kinase Inhibitors
Despite a general resistance against standard systemic anti-cancer therapy, tyrosine kinase
inhibitors (TKIs) show good results as a secondary treatment option for MTC [13].
Tyrosine kinases (TKs), or receptor tyrosine kinases (RTKs), are a family of receptors found
throughout the body. RTKs are monomers (except for the insulin-receptor), which, upon stimulation
from ligands, form dimers that cause an autophosphorylation followed by a conformational change
and activation of tyrosine kinases. This triggers the Ras/Raf/MAPK signaling cascade, along with
possible concurrent signaling via the phosphoinositide 3-kinase (PI3K) pathway. This leads to changes
in transcriptional factors and consequently changes in expression patterns of genes involved in cell
growth, differentiation, and cell survival [14]. With TK being the target for growth factors (GF), TKIs
are important anticancer drugs, preventing tumor growth by acting anti-angiogenically [15].
Tissue growth, such as tumor development, necessitates a constant nutrient supply, which is
accomplished by the development of new blood vessels from pre-existing ones, a process termed
angiogenesis. This development is regulated by multiple GFs, but most significantly by vascular
endothelial growth factors (VEGFs), which stimulate vascular permeability, cell proliferation, and cell
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survival in both the physiological and pathophysiological angiogenesis. Other GFs also contribute to
angiogenesis. Amongst these, the fibroblast GF (FGF), hepatocyte GF (HGF), and platelet derived GF
(PDGF) are of most importance [16,17].
The VEGF family comprises five members (VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental
GF (PGF)), which interact with their corresponding RTKs, the VEGF receptors (VEGFRs). VEGFRs
can be divided into three types, and while VEGFR-1 and -2 are expressed in vascular endothelial
cells, VEGFR-3 is expressed in lymphatic endothelial cells. All VEGFRs are characterized by different
specificities (Table 1) [18].
Table 1. Overview of compatible vascular endothelial growth factors (VEGFs) and VEGF
receptors (VEGFRs).
VEGFR VEGF
VEGFR-1 VEGF-A, VEGF-B and placental growth factors (PGF)
VEGFR-2 VEGF-A and proteolytically cleaved forms of VEGF-C and VEGF-D
VEGFR-3 VEGF-C and VEGF-D
Two pharmacological approaches are available to interrupt VEGF signaling. First is the direct
inhibition of VEGF using monoclonal antibodies, preventing the binding to their receptors [19].
However, it has been shown that cancers are able to develop resistance towards these drugs, which in
turn can lead to an increase in expression of hepatocyte growth factor receptor MET, the only known
receptor for HGF. Consecutively, this leads to an increase in aggressiveness and metastatic progression
of the tumor [20].
The second pharmacological approach to prevent tumor progression is the inhibition of the RTKs,
prompting a blockage of consecutive intracellular phosphorylation cascades. This is the method of
action of cabozantinib, pazopanib, and vandetanib. Cabozantinib, an orally administered TKI, is given
in doses ranging from a daily dose of 0.08 mg/kg to 11.52 mg/kg and inhibits MET, VEGFR-2, and
RET, thus blocking the phosphorylation cascade and thus suppressing any oncogenic effects. At the
same time, the problem of a potential upregulation of MET expression due to VEGF inhibition is
eliminated [21].
Pazopanib is another orally administered TKI, used in doses of 800 mg/d [22], inhibiting all
VEGFRs, the PDGF receptor (PDGFR), and c-Kit tyrosine kinases [23]. It has a terminal elimination
half-life of 91.3 h, reaches steady state plasma-levels after 15 d and is metabolized in the liver by
cytochrome P4502C8 (CYP2C8) [24].
Vandetanib is one of the first TKIs tested in patients suffering from MTC and has been approved
for treatment of the disease in 2011 in the U.S. and in 2012 in Europe. It is bound to plasma proteins
by more than 99.9% and has a terminal eliminiation half-life of 31.1 h with a main secretion via the
feces (82.2%). The mean bioavailability was found to be 21.4% [25]. Vandetanib’s main targets are
RET, VEGFR-2, and epidermal growth factor receptor EGFR [24–27]. The usual dosage ranges from
100 mg/d to 300 mg/d [26–31]. Vandetanib’s pharmacokinetic properties were linear over the dosage
range of 50 to 1200 mg/d. The maximum plasma concentration of 857 ng/mL is usually reached after
6 h. Vandetanib is highly protein-bound (92–94%) and has a terminal excretion half-life of 20 d. It is
metabolized by cytochrome P4503A4 (CYP3A4) and predominantly excreted via the feces and urine
(44% and 25%, respectively) [32].
The modes of actions of the three discussed TKIs are illustrated in Figure 1.
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Figure 1. Chemical structures and modes of action of pazopanib, cabozantinib, and vandetanib. The red
T-arrows indicate inhibition on receptor signaling. AKT: Protein kinase B; BAD: BCL2 associated agonist
of cell death; c-Kit: stem cell growth factor receptor, EGFR: epidermal growth factor receptor; ERK:
extracellular regulated kinase, MAPK: mitogen activated protein kinase, MEK: methyl ethyl ketone,
MET: methionine, MDM2: mouse double minute 2, mTOR: mammalian target of rapamycin, NF-kB:
nuclear factor kappa B, PDGFR: platelet derived growth factor receptor, PI3K: phosphoinositide 3
kinases, RAF: rapidly accelerated fibrosarcoma, RAS: rat sarcoma, RET: rearranged during transfection,
STAT: signal transducers and activators of transcription.
3.1. Adverse Effects
The inhibitory effect of VEGF signaling resulting from many TKIs, such as cabozantinib,
pazopanib, or vandeatnib, is not only a local, tumor-selective effect. TKIs also act systemically and
can give a rise to a multitude of different AEs, although they are generally better tolerated than other
cytotoxic chemotherapeutics. Not surprisingly, among the most common AEs are those related to the
cardiovascular system, such as hypertension or chronic heart failure in combination with dermatologic
(skin rash, skin and hair hypopigmentation, alopecia), abnormal laboratory value (ane ia, leucopenia)
or ore unspecific AEs such as diarrhea, nausea, fatigue, or anorexia [33–36]. While most of these
AEs require a strict management to ensure patient compliance and preservation of quality of life as
established for other chemotherapeutics, the cardiovascular side effects need special attention, as they
are very specific to this class of drugs and potentially life-threatening when untreated. The underlying
mechanisms of this drug-induced hypertension are to date not fully clarified [37]. In animal models,
VEGF stimulation has been shown to result in the production of nitric oxide (NO), presumably through
the PI3K pathway, leading to NO-mediated hemodynamic changes e.g., vasodilation and increased
vascular permeability, thus reducing the total peripheral resistance (TPR) and decreasing the blood
pressure [38]. Another animal study demonstrated that inhibition of the VEGF signaling cascade by
blocking VEGFR2 via antibodies results in reduced levels of NO and the development of hypertension,
thereby providing a possible explanation for the TKI-induced hypertension [37].
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It was also suggested that the onset of hypertension during TKI-treatment might be connected to
the reduction of capillary density. The number of small vessels is of significant importance for the TPR.
A decrease leads to greater resistance and consequently to higher blood pressure. Using side stream
dark field imaging, it has been shown that the number of mucosal capillaries decreased after the onset
of TKI treatment. However, the study was unable to conclude whether the lack of NO or the reduced
number of small vessels was the source of origin for the observed hypertension [39].
It has also been demonstrated that VEGF and endothelin-1 (ET1) mutually mediate each other’s
gene expression levels, resulting in an increased protein synthesis and release. With ET1 being a
potent vasoconstrictor under normal physiological conditions, and VEGF generally being a vasodilator,
thereby neutralizing each other’s effect, it might be assumed that pharmacological blocking of VEGFR
could lead to hypertension via overexpression of ET1 [37,40].
Lastly, in a study investigating the TKI sorafenib using parameters such as the central aortic
augmentation index (CAIx) and the aortic pulse wave velocity (APWV), treatment with TKI has
shown to significantly increase aortic stiffness, suggesting that vascular stiffness could contribute to
drug-induced hypertension. However, the study was not able to clarify whether the stiffness occurred
as a result of hypertension or was a cause of it [41]. Figure 2 shows a graphical representation of the
most important findings.
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3.2. Efficacy of Cancer Drug Treatment
Previously, pazopanib showed promising results for the treatment of thyroid cancer, reporting
effects in DTC with a 49% Response Evaluation Criteria in Solid Tumors (RECIST) partial tumor
response rate (PR), but the agent had no effect in ATC. Therefore, a study on the efficacy of pazopanib
in metastatic and progressive MTC was conducted, and had demonstrated promising results. The study
met its pre-trial criteria for success with a RECIST tumor response rate of 14.3%, further estimated the
median progression-free survival (PFS) to be 9.4 months, and the median overall survival 19.9 months,
providing a considerable treatment alternative for progressive MTC [22].
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A double-blind phase III trial compared the primary end point, PFS after treatment with
cabozantinib compared to a placebo in the treatment of progressive MTC. This trial found PFS to be
significantly longer with cabozantinib, with a median of 11.4 months compared to only 4.0 months
when using placebo. The estimated tumor response rate for cabozantinib and placebo is 28% and 0%,
respectively, with results varying independently on RET-status, thus making it a promising treatment
option [34]. However, the difference for the secondary study end point, overall survival (OS), was
found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib
had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85;
95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients
treated with cabozantinib a 20.68% longer survival period compared to the placebo group. In addition,
the study demonstrated that patients with RET M918T-positive tumors may have a greater benefit of
cabozantinib than patients of the RET M918T-negative subgroup [42].
After promising phase 2 trials, which showed 20% PR plus an extra 53% of stable disease (SD)
in patients suffering from unresectable, locally advanced or metastatic MTC treated with 300 mg/d
vandetanib [28], 16% PR, and 53% SD under a 100 mg/d vandetanib regimen [29] in a similar patient
cohort, and 47% PR in children and adolescents with locally advanced or metastatic hereditary
MTC [31], a larger study was conducted. This multicenter, randomized, phase 3 trial included a total
of 331 patients with locally advanced or metastatic MTC and aimed to compare efficacy and safety
of 300 mg/d vandetanib (n = 231) with placebo (n = 100). It was shown that vandetanib therapy
significantly prolonged PFS (30.5 months vs. 19.3 months; hazard ratio 0.46; 95% CI 0.31 to 0.69;
p < 0.001) and resulted in 45% PRs [30]. In addition, positive effects of vandetanib were also found
for objective response rate, disease control rate, and biochemical response (all p < 0.001). No definite
statements could be made about OS, as at the time of data publication, the median follow-up period of
24 months was not yet long enough (HR 0.89; 95% CI 0.48 to 1.65).
An overview of the observed adverse effects connected to therapy with the three TKIs is given in
Table 2.
Table 2. Adverse effects during tyrosine kinase inhibitor (TKI)-therapy of progressive medullary
thyroid cancer (MTC).
Drug Most Common Adverse Events(Any Grade)
Dose
Reductions
Discontinuations
Due to Aes
Cabozantinib [34]
Diarrhea (63%; 135/214)
Hand-foot syndrome (50%; 107/214)
Nausea (43%; 92/214)
Fatigue (41%; 87/214)
Hypertension (33%; 70/214)
79%; 169/214 16%; 35/214
Pazopanib [22]
Diarrhea (77%; 27/35)
Fatigue (63%; 22/35)
Hypertension (52%; 18/35)
Nausea (52%; 18/35)
Anorexia (46%; 16/35)
40%; 14/35 8.6%; 3/35
Vandetanib [28]
Diarrhea (56%; 130/231)
Rash (45%; 104/231)
Nausea (33%; 77/231)
Hypertension (32%; 73/231)
Headache (25%; 59/231)
35%; 81/231 12%; 28/231
Rates are given in %, followed by absolute numbers of affected patients/total patients.
Many of the reported AEs can be very uncomfortable or even disabling for the affected patient,
leading to loss of compliance or even discontinuation of the medication, but do not necessarily pose a
severe health risk per se. Most of the common AEs like diarrhea, nausea, or fatigue can be relieved
by measures such as dose adjustments, control of blood and electrolyte parameters, adjusting the
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patient’s daily schedule, and the additional administration of drugs such as loperamide. Hypertension,
however, especially if left untreated, can lead to potentially life-threatening complications and should
be controlled tightly over the course of the TKI therapy. In the pazopanib trial, 2.8% of treated patients
had to stop treatment because of hypertension [22]. The assessment of the actual clinical importance
of TKI-induced hypertension can be complex as a result of the association of different complications
with hypertension in different age-groups, or inter-personal variations in how complications from
hypertension affect quality of life. Nonetheless, it is a well-known fact that hypertension is associated
with an increased risk of developing several high-mortality cardiovascular (CV) diseases, the three
strongest associations being found with intracerebral hemorrhage, subarachnoid hemorrhage, and
stable angina [43].
3.3. Management of Drug-Induced Hypertension
When making a management plan for the drug-induced hypertension, it is important to know if
there are any interactions between the antihypertensive drugs and the chosen TKI. Both cabozantinib
and pazopanib are metabolized by CYP3A4. Therefore, drugs altering the efficacy of this enzyme
should be avoided in order to maintain the balance between the administered dose and the plasma
clearance within the therapeutic interval [44,45].
One of the problems with TKI-induced hypertension is the lack of NO-production when blocking
VEGF signaling. It is therefore imaginable that prescribing NO donors to hypertensive patients would
induce a vasodilation, balancing the hypertensive side effects of the drugs. In a number of cases, the
intake of donors, such as isosorbide dinitrate, isosorbide mononitrate, or molsidomine, has proven to
significantly decrease hypertension, lowering the blood pressure to almost pre-treatment status [46,47].
Despite promising clinical efficacy and the development of a suggested treatment plan, the effect still
needs to be evaluated in larger clinical trials [48].
As detailed above, the vasoconstrictor ET1’s may also be involved in the development of
drug-induced hypertension as a result of overexpression. Endothelin receptor antagonists (ERAs)
are already used for treating pulmonary arterial hypertension and have shown effects in treating
systemic hypertension as well, but because of the side-effect complications such as liver toxicity and
fluid retention, they are not the drug of choice for essential hypertension. However, it might find its
clinical relevance in this case since the hypertension is TKI-induced [49,50].
Drug-induced hypertension is also treatable with more classic agents. Among these options,
first-in-line therapies include angiotensin converting enzyme (ACE) inhibitors, angiotensin II
receptor blockers, non-dihydropyridine calcium channel blockers, and beta-blockers. Some of
these drugs are able to increase NO-signaling and based on the suggested positive effects of NO
on hypertension, drugs with this ability, like the beta-blocker nevibolol, could be of particular
interest. The two calcium-antagonists verapamil and diltiazem are both capable of inhibiting
CYP3A4, and for this reason, they are interacting with the metabolism of pazopanib and cabozantinib.
These antihypertensive drugs should therefore be excluded from consideration when managing the
TKI-induced hypertension.
Diarrhea is also an AE to TKI-treatment, which makes the electrolyte depleting drugs such as
diuretics less important treatment options [51].
3.4. Ongoing Clinical Trials
There is still a need to validate cabozantinib, pazopanib, and vandetanib as a therapeutic option
in MTC. Therefore, numerous clinical trials are currently investigating the efficacy, safety, and optimal
doses of the drugs according to toxicity. An overview of currently ongoing trials is given in Table 3.
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Table 3. Overview of currently ongoing clinical trials studying pazopanib, cabozantinib, and vandetanib in MTC [52].
Drug Title Design Objective Status Results
Pazopanib
A Phase II Study of GW 786034
(Pazopanib) in Advanced Thyroid
Cancer NCT00625846
Interventional
Open label
To establish safety and efficacy of pazopanib in
Differentiated thyroid cancer (DTC), Medullary
thyroid cancer (MTC), and Anaplastic thyroid cancer
(ATC), how the drug impacts VEGF plasma levels and
the changes is thyroglobulin and its relationship with
tumor response.
Active, Not
recruiting
The study found positive partial response rates in
DTC, but has no overall survival (OS) measure.
Adverse effects (AEs) occurred in 43% but
generally mild. It showed to be a positive
treatment option [53].
Cabozantinib
A Randomized, Double-blind Study To
Evaluate the Efficacy and Safety of
Cabozantinib (XL184) at 60 mg/Day
Compared to a 140 mg/Day in
Progressive, Metastatic Medullary
Thyroid Cancer Patients NCT01896479
Interventional
Double-blind
Randomized
To study the efficacy and safety of cabozantinib when
comparing to different doses: 60 mg and 140 mg with
placebo. Efficacy measures are progression free
survival and overall response rate. Safety measures is
a comparison between fewer adverse effects and the
efficacy measures.
Recruiting −
An Open-Label, Expanded Access
Study of Cabozantinib (XL184) in
Subjects With Unresectable, Locally
Advanced, or Metastatic Medullary
Thyroid Cancer NCT01683110
Expanded access
Open Label Provide access to cabozantinib
Approved for
marketing −
An International, Randomized,
Double-Blinded, Phase 3 Efficacy Study
of XL184 Versus Placebo in Subjects
With Unresectable, Locally Advanced,
or Metastatic Medullary Thyroid
Cancer NCT00704730
Interventional
Double-blind
Randomized
This study is comparing efficacy measures such as
progression-free survival, overall survival and
objective response rate between patients receiving
cabozantinib and placebo.
Unknown, has
results
The study found a statistically significant increase
in Progression free survival (PFS) using
cabozantinib compared to placebo, an objective
response rate of 28% (higher for RET M918T
positive subgroup) and an improved OS, although
not significantly better than placebo [42,43].
A Phase 1 Dose-Escalation Study of the
Safety and Pharmacokinetics of XL184
Administered Orally to Subjects With
Advanced Malignancies NCT00215605
Interventional
Open label
This study is evaluating the safety, tolerability,
maximum tolerated dose and dose-limiting toxicity of
cabozantinib. It also evaluates plasma
pharmacokinetics and renal elimination.
Measurements include progression-free survival and
tumor response.
Completed
49% of patients with MTC showed tumor
shrinkage and 68% of these showed stable disease
for over 6 months. Of all patients included, 90%
experienced AEs, but 43% were of grade 1 or 2.
The drug was considered to have a satisfactory
safety profile [34]
A Phase 1 Study of XL184
(Cabozantinib) in Children and
Adolescents With Recurrent or
Refractory Solid Tumors, Including
CNS Tumors NCT01709435
Interventional
Open label
It is evaluating maximum tolerated dose and
recommended phase II dose of cabozantinib in
children with solid tumors incl. childhood thyroid
gland medullary carcinomas. They also describe
toxicities, pharmacokinetics and evaluate
overall survival.
Active, Not
recruiting −
Phase 2 Trial of XL184 (Cabozantinib)
an Oral Small-Molecule Inhibitor of
Multiple Kinases, in Children and
Young Adults With Refractory
Sarcomas, Wilms Tumor, and Other
Rare Tumors NCT02867592
Interventional,
Open label
Determine the objective response rate, toxicities, and
pharmacokinetics of cabozantinib in children and
young adults with rare tumors.
Recruiting
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Table 3. Cont.
Drug Title Design Objective Status Results
Vandetanib
European, Observational, Prospective
Study to Evaluate the Benefit/Risk of
Vandetanib in RET Mutation Negative
and Positive Patients With
Symptomatic, Aggressive, Sporadic,
Unresectable, Locally
Advanced/Metastatic Medullary
Thyroid Cancer NCT01945762
Observational
Assessment of the risk/benefit of 300 mg/d
vandetanibin RET positive and RET negative patients
with MTC.
Recruiting
Phase I/II Trial of Vandetanib (ZD6474,
ZACTIMA) in Children and
Adolescents With Hereditary Medullary
Thyroid Carcinoma NCT00514046
Interventional
Investigation of activity of vandetanib in children and
adolescents with MTC caused by multiple endocrine
neoplasia genetic disorder. Assessment of safety,
tolerability, and survival in the study group.
Active, not
recruiting
A Randomized, Int., Open-Label Phase
III Study to Assess the Effect of a Patient
Outreach Program on the Percentage of
Time Patients With Locally Advanced or
Metastatic MTC Experience Grade 2 or
Higher AEs in the First 12 Months
of Treatment With
Vandetanib NCT01298323
Randomized,
Open label
Determine if contacting patients with MTC more
frequently results in earlier detection and treatment of
signs and symptoms of AEs during the first
12 months on vandetanib treatment.
Active, not
recruiting
An International, Randomised,
Double-Blind, Two-Arm Study To
Evaluate The Safety And Efficacy Of
Vandetanib 150 And 300mg/Day In
Patients With Unresectable Locally
Advanced Or Metastatic Medullary
Thyroid Carcinoma With Progressive Or
Symptomatic Disease NCT01496313
Interventional,
Randomized,
Double-blind
Comparison of safety and efficacy of 150 and
300 mg/d vandetanib in patients with MTC.
Active, not
recruiting
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4. Discussion
A concern when treating any condition is that the efficacy of the chosen drug should always be
sufficient enough to make up for the often rather extensive AEs. As specified above, hypertension is a
common AE in treatments with TKIs [3], but also other serious AEs such as proteinuria, hemorrhage,
pulmonary embolism/venous thrombosis, nausea, vomiting, diarrhea, and skin toxicity are of
relevance and affect quality of life [26]. Hypertension as a side effect is not a problem, patients complain
about it due to its asymptomatic nature. Therefore, it is not hypertension, but the cardiovascular
complications following hypertension that are of concern and necessitate treatment [43].
A recent study investigated the predisposing factors for the development of hypertension during
treatment with an anti-VEGF therapy like TKI. They found that pre-existing hypertension, an age
of over 60 years, and a BMI above 25 are factors of significance. This should be kept in mind before
starting treatment [54]. However, with the poor prognosis of a mean 10-year survival rate of 40% for
progressive MTC [12], and with these drugs being administered in late stages of the disease, it raises
the question whether hypertension is a severe concern, given that the TKIs are only life-prolonging by
prevention of tumor growth—hence not curative—and only provide a somewhat short life extension.
The median overall survival from treatment with pazopanib is approximately 20 months, and for
treatments with cabozantinib between 20–45 months [22,43]. This relatively short treatment-period
differentiates the problem with drug-induced hypertension from chronic essential hypertension,
mainly because it is uncertain how long the patient has to suffer from hypertension in order to develop
complications. Furthermore, antihypertensive drugs have AEs on their own, and by managing the
drug-induced hypertension more AEs, or worsening of TKI-induced AEs, are likely to also affect the
overall quality of life. Therefore, there is a fine line to walk. The caregiver has to personalize the
treatment to each patient coming with a different health status both mentally and physically, and with
different tolerance levels when it comes to the severity of AEs influencing the patient’s quality of life.
Additionally, not treating hypertension in TKI-receiving patients could result in serious AEs such as
cardiotoxicity worsening as a result of the high blood pressure. The treatment should therefore still be
advised [55], making it a matter of finding the best treatment method.
Interestingly, it was found that the overall survival was significantly longer amongst those
patients developing hypertension. This could indicate that hypertension may be a biomarker for the
drug’s efficacy [54], and it might therefore correlate positively with a greater benefit of TKI treatment.
The risks of death from complications associated with hypertension are believed to be no greater than
the risk of death from MTC itself, still shifting the risk-benefit-ratio in favor of the TKI treatment.
Tyrosine kinase inhibitors like pazopanib, cabozantinib, or vandetanib act by inhibiting the VEGF
signaling cascade and have an anti-angiogenetic effect, preventing tumor growth and providing a
promising treatment option to otherwise untreatable cancers. The drugs do not come without AEs
though, the most common effect is hypertension. Hypertension is manageable in most cases, either
through a lowering of TKI doses or through treatment with antihypertensive drugs. Unfortunately,
in a few cases, the hypertension is so severe that the risk-benefit-ratio requires the discontinuation of
TKI treatment. In all other cases, treatment with TKIs significantly prolongs progression-free survival
for patients with progressive MTC. In addition, the treatment also prolongs overall survival, though
not always to a statistically significant level. Therefore, developing treatment strategies for the AEs are
required in order to secure TKI treatment for all patients with progressive MTC.
At the moment, the process of finding the optimal dose for each patient is a delicate balance
between still manageable AEs with an acceptable quality of life and a significant prolongation of PFS
or OS. Finding suitable biomarkers for the prediction of TKI efficacy would therefore be an important
contribution towards the optimization of personalized therapy. One promising candidate for this
purpose is the RET mutation status. For vandetanib, however, benefits were observed for all patients,
regardless of their RET status [28]. In the case of cabozantinib it was found that patients with a RET
M918T mutation had the greatest benefit for PFS vs. placebo (R, 0.15; 95% CI, 0.08–0.28; p < 0.0001) [56].
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As demonstrated in the various clinical studies, the prevalence of AEs is still high and can in some
cases lead to considerable rates of dose reduction or even termination of the treatment. It is therefore a
major goal to deliver the drugs in a way that systemic AEs are minimized. One possibility for this are
nanoscale drug delivery vehicles. In a recent study, a photoactivatable multi-inhibitor nanoliposome
had been developed, which included cabozantinib. With the help of this contruct, it was possible to
reduce tumor size and decrease metastasis after injection and near-infrared irradiaton of the tumor
in a mouse pancreatic cancer model [57]. Furthermore, it was speculated that TKI-treatment might
facilitate the delivery of liposme delivery via a so-called tumor normalization, but early experiments
utilizing a mouse model of a lung cancer xenograft did not reveal any difference in intra-tumoral
liposome concentration between pazopanib + and − mice [58].
5. Methods
As tools for finding the literature for this review, several online databases and registers were
used, such as PubMed (https://www.ncbi.nlm.nih.gov/pubmed), Scopus (www.scopus.com), and
ClinicalTrials (www.clinicaltrials.com). Articles and their references, only if written in English, were
reviewed and those who were found relevant were included in this review. To limit the search in these
databases, the following keywords were used: “Thyroid Cancer”, “Medullary Thyroid Cancer”,
“Medullary Thyroid Cancer AND Pazopanib”, Medullary Thyroid Cancer AND Cabozantinib”,
“Hypertension”, “Pazopanib AND hypertension”, “Cabozantinib AND Hypertension”, “Medullary
Thyroid Cancer AND Vandetanib“, and lastly “Vandetanib AND hypertension”.
On 08/31/2018 a search in PubMed for “Thyroid Cancer” gave 71443 results, “Medullary Thyroid
Cancer” gave 7550 results, “Medullary Thyroid Cancer AND Pazopanib” gave 14 results, “Medullary
Thyroid Cancer AND Cabozantinib” gave 138 results, “Hypertension” gave 470284 results, “Pazopanib
AND hypertension” gave 139 results, “Cabozantinib AND Hypertension” gave 36 results, Medullary
Thyroid Cancer AND Vandetanib” gave 206 results, and lastly “Vandetanib AND Hypertension” gave
61 results.
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Abbreviations
AE(s) Adverse effect(s)
AKT Protein kinase
APWV Aortic pulse wave velocity
ATC Anaplastic thyroid cancer
BAD BCL2 associated agonist of cell death
CAIx Central aortic augmentation index
c-Kit Stem cell growth factor receptor
CV Cardiovascular
CYP3A4 Cytochrome P4503A4
DBP Diastolic blood pressure
DTC Differentiated thyroid cancer
EGF Epidermal growth factor
ERA Endothelin receptor antagonist
ERK Extracelluar regulated kinase
FC Follicular cell
FGF Fibroblast growth factor
FMTC Familial medullary thyroid cancer
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FTC follicular thyroid cancer
GF Growth factors
HGF Hepatocyte growth factor
MAPK Mitogen activated protein kinase
MEK Methyl ethyl ketone
MET Methionine
MDM2 Mouse double minute 2
MTC Medullary thyroid cancer
mTOR Mammalian rarget of rapamycin
NF-kB Nuclear factor kappa B
OS Overall survival
PDGF Platelet derived growth factor
PDGFR Platelet derived growth factor receptor
PDTC Poorly differentiated thyroid cancer
PFS Progression free survival
PI3K Phosphoinositide 3 kinases
PR Partial response
PTC Papillary thyroid cancer
RAF Rapidly accelerated fibrosarcoma
RAS Rat sarcoma
RECIST Response Evaluation Criteria in Solid Tumors
RET Rearranged during Transfection
RTK Receptor tyrosine kinase
SBP Systolic blood pressure
STAT Signal transducers and activators of transcription
TK Tyrosine kinase
TKI Tyrosine kinase inhibitor(s)
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
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